{"protocolSection": {"identificationModule": {"nctId": "NCT03683576", "orgStudyIdInfo": {"id": "GB001-2001"}, "organization": {"fullName": "Gossamer Bio Inc.", "class": "INDUSTRY"}, "briefTitle": "GB001 in Adult Subjects With Moderate to Severe Asthma", "officialTitle": "A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma"}, "statusModule": {"statusVerifiedDate": "2021-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-10-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-07-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-08-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-09-11", "studyFirstSubmitQcDate": "2018-09-21", "studyFirstPostDateStruct": {"date": "2018-09-25", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-07-23", "resultsFirstSubmitQcDate": "2021-08-19", "resultsFirstPostDateStruct": {"date": "2021-08-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-08-20", "lastUpdatePostDateStruct": {"date": "2021-09-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["GB001", "eosinophilic asthma", "moderate asthma", "severe asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 481, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo once per day (QD) for 24 weeks", "interventionNames": ["Drug: Placebo"]}, {"label": "GB001 20 mg", "type": "EXPERIMENTAL", "description": "GB001 20 mg QD for 24 weeks", "interventionNames": ["Drug: GB001"]}, {"label": "GB001 40 mg", "type": "EXPERIMENTAL", "description": "GB001 40 mg QD for 24 weeks", "interventionNames": ["Drug: GB001"]}, {"label": "GB001 60 mg", "type": "EXPERIMENTAL", "description": "GB001 60 mg QD for 24 weeks", "interventionNames": ["Drug: GB001"]}], "interventions": [{"type": "DRUG", "name": "GB001", "description": "film-coated oral tablet", "armGroupLabels": ["GB001 20 mg", "GB001 40 mg", "GB001 60 mg"]}, {"type": "DRUG", "name": "Placebo", "description": "film-coated oral tablet", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of Participants Who Experience Worsening of Asthma by Week 24", "description": "Proportion of participants who experience worsening of asthma by Week 24 as defined by at least 1 of the following:\n\n* On 2 consecutive days, morning (AM) peak expiratory flow (PEF) \u2264 75% of mean AM PEF measured over the last 7 days of the Run-in\n* Forced expiratory volume in 1 second (FEV1) \\< 80% of baseline\n* Increase in rescue medication use of \u2265 6 puffs/day on 2 consecutive days compared to mean use over the last 7 days of the Run-in\n* Increase in Asthma Control Questionnaire 5 (ACQ-5; see Outcome Measure 2 for description) score of \u2265 0.5 compared to baseline\n* The occurrence of a severe asthma exacerbation (asthma attack) defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.", "timeFrame": "up to Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 24 in Asthma Control Questionnaire - 5 (ACQ-5) Score", "description": "The ACQ-5 is a 5-item questionnaire which has been developed as a measure of the participant's asthma control that can be quickly and easily completed. The questions are designed to be self-completed by the participant. The 5 questions enquire about the frequency and/or severity of symptoms in the prior week (nocturnal awakening, activity limitation, shortness of breath, wheeze). The response options for each of these questions consists of a zero (no impairment/limitation) to 6 (total impairment/limitation) scale.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline to Week 24 in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "Pre-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.", "timeFrame": "Baseline, Week 24"}, {"measure": "Time to First Asthma Worsening", "description": "Time to first asthma worsening is defined as the time from the date of the first dose of study treatment to the first date that any of the components of asthma worsening endpoint is met. See Outcome Measure 1 for the definition of asthma worsening.", "timeFrame": "up to Week 24"}, {"measure": "Annualized Rate of Severe Asthma Exacerbations", "description": "A severe asthma exacerbation is defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.", "timeFrame": "up to Week 24"}, {"measure": "Change From Baseline to Week 24 in Post-Bronchodilator FEV1", "description": "Post-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline to Week 24 in Morning Peak Expiratory Flow (AM PEF)", "description": "AM PEF was measured by participants using an electronic diary.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Participants With a Treatment-Emergent Adverse Event (AE)", "description": "An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to study treatment. Abnormal laboratory test results or other safety assessments, including those that worsened from baseline, that were considered clinically significant in the medical and scientific judgment of the investigator were to be reported as AEs.", "timeFrame": "From first dose of study treatment through Week 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* A diagnosis of asthma by a physician at least 12 months before Screening Visit.\n* Treated with medium or high dose inhaled corticosteroid (ICS) plus additional controller for at least 12 months prior to Screening Visit. Subjects must maintain a stable ICS dose regimen during the 4 weeks prior to the Screening Visit.\n* Forced Expiratory Volume in 1 second (FEV1) of \u2264 85% of predicted normal\n* Demonstrated reversibility of at least 12% in FEV1\n* Evidence of uncontrolled asthma\n* Eosinophilic asthma\n* No changes in ICS dose and compliant with standard of care asthma therapy during run-in period.\n\nExclusion Criteria\n\n* Current smokers (any substance)\n* Serious co-morbidities\n* Fridericia's correction QT factor (QTcF) \u2265450 msec (male) or \u2265470 msec (female)\n* Use of other investigational drugs within 30 days, or within 5 half-lives, whichever is longer, prior to Screening Visit\n* Regular use of systemic corticosteroids or immunosuppressive treatments or monoclonal antibodies for asthma\n* Pregnant or breastfeeding\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "74 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Clinical Research Center of Albama, LLC", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Banner University of Arizona Medical Center", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "California Allergy and Asthma Medical Group", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Southern California Institute for Respiratory Diseases, Inc.", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "North Bay Clinical Trials, Inc", "city": "Napa", "state": "California", "zip": "94558", "country": "United States", "geoPoint": {"lat": 38.29714, "lon": -122.28553}}, {"facility": "Allergy, Asthma & Sinus Consultants, Inc", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Integrated Research of Inland, Inc.", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Allergy & Asthma Medical Group and Research Center, A P.C.", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Allergy and Asthma Associates of Santa Clara Valley Research Center", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Bensch Clinical Research LLC", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Pulmonary Associates", "city": "Colorado Springs", "state": "Colorado", "zip": "80909", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Yale New Haven Hospital", "city": "New Haven", "state": "Connecticut", "zip": "06519", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Central Florida Pulmonary Group, PA", "city": "Altamonte Springs", "state": "Florida", "zip": "32701", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Central Florida Pulmonary Group, PA", "city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Emerald Coast Research Associates", "city": "Panama City", "state": "Florida", "zip": "32405", "country": "United States", "geoPoint": {"lat": 30.15946, "lon": -85.65983}}, {"facility": "Allergy and Asthma Diagnostic Treatment Center", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Clinical Research Trials of Florida, Inc.", "city": "Tampa", "state": "Florida", "zip": "33607", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "The Emory Clinic", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Atlanta Allergy & Asthma Clinic, PA,", "city": "Marietta", "state": "Georgia", "zip": "30060", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"facility": "Atlanta Allergy & Asthma Clinic, PA", "city": "Stockbridge", "state": "Georgia", "zip": "30281", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Treasure Valley Medical Research", "city": "Boise", "state": "Idaho", "zip": "83706", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Rush University Medical Center", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Allergy & Asthma Specialists, PSC", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "John Hopkins Asthma and Allergy Center", "city": "Baltimore", "state": "Maryland", "zip": "21224", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "University of Michigan Medicine", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Clinical Research Institute, Inc.", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Washington University School of Medicine", "city": "Saint Louis", "state": "Missouri", "zip": "63108", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Atlantic Research Center, LLC", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "American Health Research", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Clinical Research of Charlotte", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Wake Forest Baptist Health", "city": "Winston-Salem", "state": "North Carolina", "zip": "27104", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Bernstein Clinical Research Center, LLC", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Cleveland Clinic", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Oklahoma Institute of Allergy & Asthma Clinical Research, LLC", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73131", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Crisor, LLC", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Allergy and Clinical Immunology Associates", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Berks Schuylkill Respiratory Specialists, Ltd.", "city": "Wyomissing", "state": "Pennsylvania", "zip": "19610", "country": "United States", "geoPoint": {"lat": 40.32954, "lon": -75.96521}}, {"facility": "AAPRI Clinical Research Institute", "city": "Warwick", "state": "Rhode Island", "zip": "02886", "country": "United States", "geoPoint": {"lat": 41.7001, "lon": -71.41617}}, {"facility": "Clinical Research of Rock Hill", "city": "Rock Hill", "state": "South Carolina", "zip": "29732", "country": "United States", "geoPoint": {"lat": 34.92487, "lon": -81.02508}}, {"facility": "Corsicana Medical Research, LLC", "city": "Corsicana", "state": "Texas", "zip": "75110", "country": "United States", "geoPoint": {"lat": 32.09543, "lon": -96.46887}}, {"facility": "Western Sky Medical Research", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Allergy and Asthma Research Center, PA", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Pulmonary Research of Abingdon, LLC", "city": "Abingdon", "state": "Virginia", "zip": "24210", "country": "United States", "geoPoint": {"lat": 36.70983, "lon": -81.97735}}, {"facility": "MultiCare Institute for Research & Innovation", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "University of Wisconsin School of Medicine and Public Health Asthma, Allergy, and Pulmonary Clinical Research", "city": "Madison", "state": "Wisconsin", "zip": "53792-9988", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Ordination Dr. Robert Voves", "city": "Feldbach", "zip": "8330", "country": "Austria", "geoPoint": {"lat": 46.95306, "lon": 15.88833}}, {"facility": "SALK University Hospital Salzburg, State Hospital Salzburg", "city": "Salzburg", "country": "Austria", "geoPoint": {"lat": 47.79941, "lon": 13.04399}}, {"facility": "Medical University of Vienna, Department of Internal Medicine II, Clinical Division of Pulmonolog", "city": "Vienna", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "UCL Saint-Luc - Pneumology Department", "city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Pneumocare sprl", "city": "Erpent", "country": "Belgium", "geoPoint": {"lat": 50.45116, "lon": 4.90557}}, {"facility": "UZ Gent - Department of Respiratory Medicine", "city": "Gent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "CHU de Charleroi - Site Andr\u00e9 V\u00e9sale", "city": "Montigny-le-Tilleul", "country": "Belgium", "geoPoint": {"lat": 50.38056, "lon": 4.37582}}, {"facility": "Inspiration Research Limited", "city": "Toronto", "state": "Ontario", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "CHUM - Departement de pneumologie", "city": "Montreal", "state": "Quebec", "zip": "H2X 3E4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Allergiste & Immunologue - Clinic/Outpatient Facility", "city": "Montreal", "state": "Quebec", "zip": "H3G 1L5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Centre integre universitaire de sante et de services sociaux du Nord-de-I'lle-de-Montreal - Hopital du Sacre-Coeur de Montreal", "city": "Montr\u00e9al", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Dr. Jamie Del Carpio's Clinic", "city": "Montr\u00e9al", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Inspirational Research Limited", "city": "Toronto", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "C. I. C Mauricie Inc.", "city": "Trois-Rivi\u00e8res", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "The Lung Centre, Vancouver General Hospital", "city": "Vancouver", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "St. Anne's University Hospital Brno, Institute of Clinical Immunology and Allergology", "city": "Brno", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "University Hospital Hradec Kralove, Institute of Clinical Immunology and Allergollogy", "city": "Hradec Kralove", "country": "Czechia", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"facility": "MediTrial s.r.o.", "city": "Jindrichuv Hradec", "zip": "37701", "country": "Czechia", "geoPoint": {"lat": 49.14404, "lon": 15.00301}}, {"facility": "PNEUMO-KV s.r.o.", "city": "Karlovy Vary", "zip": "36017", "country": "Czechia", "geoPoint": {"lat": 50.23271, "lon": 12.87117}}, {"facility": "Pulmonary Outpatient Clinic - Dr. Otakar Hokynar", "city": "Kralupy nad Vltavou", "zip": "27801", "country": "Czechia", "geoPoint": {"lat": 50.24107, "lon": 14.31149}}, {"facility": "University Hospital Olomouc, Department of Allergology and Clinical Immunology", "city": "Olomouc", "zip": "779 00", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Medicon a.s.", "city": "Praha 4", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Pulmonary Outpatient Clinic Rokycany s.r.o.", "city": "Rokycany", "zip": "33722", "country": "Czechia", "geoPoint": {"lat": 49.7427, "lon": 13.59459}}, {"facility": "Outpatient Allergology and Neurology Clinic Kasmed Ltd.", "city": "T\u00e1bor", "zip": "39002", "country": "Czechia", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "La Croix Rousse Hospital", "city": "Lyon", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Nord G&R Laennec Hospital", "city": "Nantes", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Centre Hospitalier Annecy Genevois", "city": "Pringy", "country": "France", "geoPoint": {"lat": 45.94622, "lon": 6.12608}}, {"facility": "NOUVEL HOPITAL CIVIL - New Civil Hospital", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin V", "city": "Homburg", "state": "Saarland", "zip": "66421", "country": "Germany", "geoPoint": {"lat": 49.32637, "lon": 7.33867}}, {"facility": "RCMS Dr. Linhoff", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Pneumologisches Studienzentrum Margrafenstrasse", "city": "Berlin", "zip": "10969", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Institut fuer Allergie - und Asthmaforschung", "city": "Berlin", "zip": "12159", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Pneumologische Praxis am Schloss", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "IKF Pneumologie GmbH & Co. KG", "city": "Frankfurt am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Pneumologicum im Suedstadtforum", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Schmid", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "BAG Prof. Hoheisel/Dr. A. Bonitz", "city": "Leipzig", "zip": "04275", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Pneumologische Praxis PD Dr. med.", "city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "KLB Gesundheitsforschung Luebeck GmbH", "city": "Luebeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz - Hospital", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Centrum Medycyny Oddechowej Mroz sp. j.", "city": "Bia\u0142ystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Malopolskie Centrum Alergologii", "city": "Krak\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ)", "city": "Krak\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Ostrowieckie Centrum Medyczne", "city": "Ostrowiec \u015awi\u0119tokrzyski", "country": "Poland", "geoPoint": {"lat": 50.92936, "lon": 21.38525}}, {"facility": "SPZOZ Proszowice", "city": "Proszowice", "country": "Poland", "geoPoint": {"lat": 50.19275, "lon": 20.28909}}, {"facility": "Gabinet Lekarski Zenon Bukowczan", "city": "Sucha Beskidzka", "country": "Poland", "geoPoint": {"lat": 49.74188, "lon": 19.59429}}, {"facility": "ALL-MED - Specjalistyczna Opieka Medyczna - Medyczny Instytut Badawczy Marek Jutel", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Centrum Medyczne Melita Medical", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "NZOZ Lekarze Specjalisci", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "SPZOZ Uniwersytecki Szpital Kliniczny nr 1", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Hospital Clinico Universitario de Santiago de Compostela", "city": "Santiago De Compostela", "state": "A Coruna", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Hospital Universitario de Bellvitge", "city": "L'Hospitalet de Llobregat", "state": "Barcelona", "zip": "08907", "country": "Spain", "geoPoint": {"lat": 41.35967, "lon": 2.10028}}, {"facility": "Instituto de Ciencias Medicas", "city": "Alicante", "zip": "03004", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Hospital Clinic de Barcelona", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Hospital Universitari Vall d'Hebron", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Hospital Universitario Doctor Peset", "city": "Valencia", "zip": "46017", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Public Institution: Dnipro Clinical Association of Urgent Medical Care under Dnipro City Council", "city": "Dnipro", "zip": "49006", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Public Institution \"City Clinical Hospital #4\" under Dnipro City Council", "city": "Dnipro", "zip": "49102", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Ivano-Frankivsk Central City Clinical Hospital", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Public Non-Profit Enterprise: City Clinical Hospital #13 under Kharkiv City Council", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "State Organization \"National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU\"", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "State Organization \"National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU\"", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Public Institution: City Clinical Hospital #6", "city": "Zaporizhia", "zip": "69035", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}, {"facility": "Public Non-Profit Enterprise City Hospital #1 under Zaporizhia City Council", "city": "Zaporizhia", "zip": "69104", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}, {"facility": "Public Enterprise \"Hospital #1\" under Zhytomyr City Council", "city": "Zhytomyr", "zip": "10002", "country": "Ukraine", "geoPoint": {"lat": 50.26487, "lon": 28.67669}}, {"facility": "Birmingham Heartlands Hospital", "city": "Birmingham", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Bradford Royal Infirmary", "city": "Bradford", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Glasgow Clinical Research Facility, Glasgow Royal Infirmary", "city": "Glasgow", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Royal Liverpool University Hospital", "city": "Liverpool", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "University Hospital Southampton", "city": "Southampton", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "35248549", "type": "DERIVED", "citation": "Moss MH, Lugogo NL, Castro M, Hanania NA, Ludwig-Sengpiel A, Saralaya D, Dobek R, Ojanguren I, Vyshnyvetskyy I, Bruey JM, Osterhout R, Tompkins CA, Dittrich K, Raghupathi K, Ortega H; LEDA Investigators. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 Aug;162(2):297-308. doi: 10.1016/j.chest.2022.02.038. Epub 2022 Mar 3."}, {"pmid": "31659803", "type": "DERIVED", "citation": "Ortega H, Fitzgerald M, Raghupathi K, Tompkins CA, Shen J, Dittrich K, Pattwell C, Singh D. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. Clin Exp Allergy. 2020 Feb;50(2):189-197. doi: 10.1111/cea.13524. Epub 2019 Nov 26."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study included a run-in period, during which eligibility for randomization was determined. 731 participants entered the run-in period, 481 of whom were randomized.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo once per day (QD) for 24 weeks"}, {"id": "FG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "FG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "FG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Randomized and treated. One participant randomized to GB001 40 mg was never treated and was therefore excluded from the Intent-to-Treat (ITT) and Safety Analysis Populations.", "achievements": [{"groupId": "FG000", "numSubjects": "120"}, {"groupId": "FG001", "numSubjects": "120"}, {"groupId": "FG002", "numSubjects": "118"}, {"groupId": "FG003", "numSubjects": "122"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "114"}, {"groupId": "FG001", "numSubjects": "116"}, {"groupId": "FG002", "numSubjects": "106"}, {"groupId": "FG003", "numSubjects": "114"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Other, Not Specified", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent to Treat (ITT) Population: all participants who were randomized and received at least 1 dose of study treatment", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "BG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "BG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "BG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "120"}, {"groupId": "BG001", "value": "120"}, {"groupId": "BG002", "value": "118"}, {"groupId": "BG003", "value": "122"}, {"groupId": "BG004", "value": "480"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.5", "spread": "11.91"}, {"groupId": "BG001", "value": "52.8", "spread": "11.81"}, {"groupId": "BG002", "value": "52.9", "spread": "13.32"}, {"groupId": "BG003", "value": "49.9", "spread": "14.37"}, {"groupId": "BG004", "value": "51.8", "spread": "12.92"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "74"}, {"groupId": "BG003", "value": "72"}, {"groupId": "BG004", "value": "308"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "50"}, {"groupId": "BG004", "value": "172"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "109"}, {"groupId": "BG003", "value": "112"}, {"groupId": "BG004", "value": "438"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "27"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "8"}]}]}, {"title": "Other, Not Specified", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "6"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "112"}, {"groupId": "BG003", "value": "116"}, {"groupId": "BG004", "value": "448"}]}]}, {"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "23"}]}]}, {"title": "Unknown or Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Proportion of Participants Who Experience Worsening of Asthma by Week 24", "description": "Proportion of participants who experience worsening of asthma by Week 24 as defined by at least 1 of the following:\n\n* On 2 consecutive days, morning (AM) peak expiratory flow (PEF) \u2264 75% of mean AM PEF measured over the last 7 days of the Run-in\n* Forced expiratory volume in 1 second (FEV1) \\< 80% of baseline\n* Increase in rescue medication use of \u2265 6 puffs/day on 2 consecutive days compared to mean use over the last 7 days of the Run-in\n* Increase in Asthma Control Questionnaire 5 (ACQ-5; see Outcome Measure 2 for description) score of \u2265 0.5 compared to baseline\n* The occurrence of a severe asthma exacerbation (asthma attack) defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "proportion of participants", "timeFrame": "up to Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.658", "lowerLimit": "0.570", "upperLimit": "0.737"}, {"groupId": "OG001", "value": "0.567", "lowerLimit": "0.477", "upperLimit": "0.652"}, {"groupId": "OG002", "value": "0.568", "lowerLimit": "0.478", "upperLimit": "0.654"}, {"groupId": "OG003", "value": "0.557", "lowerLimit": "0.469", "upperLimit": "0.642"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1425", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.674", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.398", "ciUpperLimit": "1.142", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1482", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.677", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.399", "ciUpperLimit": "1.149", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1086", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.651", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.385", "ciUpperLimit": "1.100", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Asthma Control Questionnaire - 5 (ACQ-5) Score", "description": "The ACQ-5 is a 5-item questionnaire which has been developed as a measure of the participant's asthma control that can be quickly and easily completed. The questions are designed to be self-completed by the participant. The 5 questions enquire about the frequency and/or severity of symptoms in the prior week (nocturnal awakening, activity limitation, shortness of breath, wheeze). The response options for each of these questions consists of a zero (no impairment/limitation) to 6 (total impairment/limitation) scale.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.89", "lowerLimit": "-1.05", "upperLimit": "-0.73"}, {"groupId": "OG001", "value": "-1.04", "lowerLimit": "-1.20", "upperLimit": "-0.89"}, {"groupId": "OG002", "value": "-1.04", "lowerLimit": "-1.20", "upperLimit": "-0.88"}, {"groupId": "OG003", "value": "-1.08", "lowerLimit": "-1.24", "upperLimit": "-0.92"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1647", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.36", "ciUpperLimit": "0.06", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1737", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.37", "ciUpperLimit": "0.07", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0879", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.40", "ciUpperLimit": "0.03", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "Pre-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters (L)", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.105", "lowerLimit": "0.027", "upperLimit": "0.182"}, {"groupId": "OG001", "value": "0.121", "lowerLimit": "0.041", "upperLimit": "0.200"}, {"groupId": "OG002", "value": "0.146", "lowerLimit": "0.064", "upperLimit": "0.227"}, {"groupId": "OG003", "value": "0.180", "lowerLimit": "0.102", "upperLimit": "0.257"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.7718", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.016", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.091", "ciUpperLimit": "0.123", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4562", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.041", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.067", "ciUpperLimit": "0.149", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1631", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.075", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.030", "ciUpperLimit": "0.180", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Worsening", "description": "Time to first asthma worsening is defined as the time from the date of the first dose of study treatment to the first date that any of the components of asthma worsening endpoint is met. See Outcome Measure 1 for the definition of asthma worsening.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "weeks", "timeFrame": "up to Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.57", "lowerLimit": "7.857", "upperLimit": "16.286"}, {"groupId": "OG001", "value": "17.43", "lowerLimit": "12.143", "upperLimit": "NA", "comment": "NA (Not Available) indicates the value is not estimable due to an insufficient number of observed events."}, {"groupId": "OG002", "value": "17.57", "lowerLimit": "13.429", "upperLimit": "24.286"}, {"groupId": "OG003", "value": "19.86", "lowerLimit": "14.857", "upperLimit": "NA", "comment": "NA (Not Available) indicates the value is not estimable due to an insufficient number of observed events."}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0466", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.719", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.519", "ciUpperLimit": "0.995", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1222", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.773", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.558", "ciUpperLimit": "1.071", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0304", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.698", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.505", "ciUpperLimit": "0.967", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Asthma Exacerbations", "description": "A severe asthma exacerbation is defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "up to Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.933", "lowerLimit": "0.664", "upperLimit": "1.311"}, {"groupId": "OG001", "value": "0.744", "lowerLimit": "0.517", "upperLimit": "1.070"}, {"groupId": "OG002", "value": "0.698", "lowerLimit": "0.480", "upperLimit": "1.015"}, {"groupId": "OG003", "value": "0.829", "lowerLimit": "0.585", "upperLimit": "1.174"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3382", "statisticalMethod": "Negative binomial regression model", "paramType": "Rate ratio", "paramValue": "0.797", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.501", "ciUpperLimit": "1.268", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.2248", "statisticalMethod": "Negative binomial regression model", "paramType": "Rate ratio", "paramValue": "0.748", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.469", "ciUpperLimit": "1.195", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6090", "statisticalMethod": "Negative binomial regression model", "paramType": "Rate ratio", "paramValue": "0.889", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.565", "ciUpperLimit": "1.397", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Post-Bronchodilator FEV1", "description": "Post-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.012", "lowerLimit": "-0.064", "upperLimit": "0.088"}, {"groupId": "OG001", "value": "-0.011", "lowerLimit": "-0.088", "upperLimit": "0.066"}, {"groupId": "OG002", "value": "0.047", "lowerLimit": "-0.037", "upperLimit": "0.131"}, {"groupId": "OG003", "value": "0.091", "lowerLimit": "0.015", "upperLimit": "0.166"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6645", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.023", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.127", "ciUpperLimit": "0.081", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5288", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.035", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.074", "ciUpperLimit": "0.144", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1362", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.079", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.025", "ciUpperLimit": "0.182", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Morning Peak Expiratory Flow (AM PEF)", "description": "AM PEF was measured by participants using an electronic diary.", "populationDescription": "ITT Population: all participants who were randomized and received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L/min", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.993", "lowerLimit": "-1.514", "upperLimit": "19.499"}, {"groupId": "OG001", "value": "15.115", "lowerLimit": "4.779", "upperLimit": "25.451"}, {"groupId": "OG002", "value": "22.941", "lowerLimit": "12.042", "upperLimit": "33.839"}, {"groupId": "OG003", "value": "14.581", "lowerLimit": "4.140", "upperLimit": "25.021"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3957", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "6.122", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.007", "ciUpperLimit": "20.251", "estimateComment": "GB001 20 mg vs. Placebo"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0598", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "13.948", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.578", "ciUpperLimit": "28.474", "estimateComment": "GB001 40 mg vs. Placebo"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4376", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "5.588", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.522", "ciUpperLimit": "19.698", "estimateComment": "GB001 60 mg vs. Placebo"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Treatment-Emergent Adverse Event (AE)", "description": "An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to study treatment. Abnormal laboratory test results or other safety assessments, including those that worsened from baseline, that were considered clinically significant in the medical and scientific judgment of the investigator were to be reported as AEs.", "populationDescription": "Safety Population: all participants who received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From first dose of study treatment through Week 28", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo QD for 24 weeks"}, {"id": "OG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks"}, {"id": "OG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks"}, {"id": "OG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "118"}, {"groupId": "OG003", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65.8"}, {"groupId": "OG001", "value": "65.8"}, {"groupId": "OG002", "value": "69.5"}, {"groupId": "OG003", "value": "68.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose of study treatment through Week 28", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo QD for 24 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 120, "seriousNumAffected": 9, "seriousNumAtRisk": 120, "otherNumAffected": 45, "otherNumAtRisk": 120}, {"id": "EG001", "title": "GB001 20 mg", "description": "GB001 20 mg QD for 24 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 120, "seriousNumAffected": 5, "seriousNumAtRisk": 120, "otherNumAffected": 53, "otherNumAtRisk": 120}, {"id": "EG002", "title": "GB001 40 mg", "description": "GB001 40 mg QD for 24 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 118, "seriousNumAffected": 5, "seriousNumAtRisk": 118, "otherNumAffected": 59, "otherNumAtRisk": 118}, {"id": "EG003", "title": "GB001 60 mg", "description": "GB001 60 mg QD for 24 weeks", "deathsNumAffected": 1, "deathsNumAtRisk": 122, "seriousNumAffected": 7, "seriousNumAtRisk": 122, "otherNumAffected": 55, "otherNumAtRisk": 122}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Chronic myeloid leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Small cell lung cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Mineral metabolism disorder", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Myasthenia gravis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Allergic bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Liver injury", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Ureterolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Uterine haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Uterine polyp", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Fracture displacement", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 122}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 122}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 122}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 122}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 122}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 13, "numAtRisk": 122}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 122}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 122}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 122}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 13, "numAtRisk": 122}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 118}, {"groupId": "EG003", "numAffected": 13, "numAtRisk": 122}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Gossamer Study Director", "organization": "GB001, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "email": "ClinicalTrials@gossamerbio.com", "phone": "1-866-668-4083"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-04-16", "uploadDate": "2021-07-06T20:55", "filename": "Prot_000.pdf", "size": 4356555}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-04-11", "uploadDate": "2021-07-06T20:56", "filename": "SAP_001.pdf", "size": 1051156}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-08-18", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14511", "name": "Pulmonary Eosinophilia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}]}}, "hasResults": true}